Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

Open access

Abstract

Background: Statins preferentially promote tumor-specific apoptosis by depleting isoprenoid such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. However, statins have not yet been approved for clinical cancer treatment due, in part, to poor understanding of molecular determinants on statin sensitivity. Here, we investigated the potential of statins to elicit enhanced immunogenicity of KRAS-mutant (KRAS mut) tumors. Methods: The immunogenicity of treated cancer cells was determined by western blot, flow cytometry and confocal microscopy. The immunotherapeutic efficacy of mono or combination therapy using statin was assessed in KRAS mut tumor models, including syngeneic colorectal cancer and genetically engineered lung and pancreatic tumors. Using NanoString analysis, we analyzed how statin influenced the gene signatures associated with the antigen presentation of dendritic cells in vivo and evaluated whether statin could induce CD8+ T-cell immunity. Multiplex immunohistochemistry was performed to better understand the complicated tumor-immune microenvironment. Results: Statin-mediated inhibition of KRAS prenylation provoked severe endoplasmic reticulum (ER) stress by attenuating the anti-ER stress effect of KRAS mutation, thereby resulting in the immunogenic cell death (ICD) of KRAS mut cancer cells. Moreover, statin-mediated ICD enhanced the cross-priming ability of dendritic cells, thereby provoking CD8+ T-cell immune responses against KRAS mut tumors. Combination therapy using statin and oxaliplatin, an ICD inducer, significantly enhanced the immunogenicity of KRAS mut tumors and promoted tumor-specific immunity in syngeneic and genetically engineered KRAS mut tumor models. Along with immune-checkpoint inhibitors, the abovementioned combination therapy overcame resistance to PD-1 blockade therapies, improving the survival rate of KRAS mut tumor models. Conclusions: Our findings suggest that KRAS mutation could be a molecular target for statins to elicit potent tumor-specific immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2021-002474

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 KRAS mutation renders tumors susceptible to statin. (A) Genetic information on the CRC cell lines. (B) Western blotting detecting active RAS form (GTP-bound Ras GTPase) on indicated tumor cell lines. (C) CCK8 assay results of KRASmut and KRASwt cancer cells (CT26: n=8; MC38: n=16). (D) CT26 (KRAS mutation, mouse), MC38 (KRAS wild type, mouse), HCT116 (KRAS mutation, human), and HT29 (KRAS wild type, human) cells were treated with simvastatin (10 µM) and FPP (5 µM) or GGPP (5 µM) for 24 hours, stained with Annexin-V-647, and analyzed using flow cytometry (n=4–12). (E) CCK8 assay of KRASmut and KRASwt CRC cell lines (n=3). (F) Levels of p-ERK1/2 and t-ERK1/2 on CT26 cells were assessed using flow cytometry (n=2–6). (G) Genetic information on PDCs. (H) PDCs were treated with simvastatin at the indicated conditions, and cell viability (%) was assessed using the Water Soluble Tetrazolium Salts cell proliferation assay (n=15–36). The data are shown as mean±SEM. Student’s t-test (D, H) or one-way ANOVA with Tukey’s post-hoc test (C–F) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; CRC, colorectal cancer; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; PDCs, patient-derived cancer cells.
Figure 1 KRAS mutation renders tumors susceptible to statin. (A) Genetic information on the CRC cell lines. (B) Western blotting detecting active RAS form (GTP-bound Ras GTPase) on indicated tumor cell lines. (C) CCK8 assay results of KRASmut and KRASwt cancer cells (CT26: n=8; MC38: n=16). (D) CT26 (KRAS mutation, mouse), MC38 (KRAS wild type, mouse), HCT116 (KRAS mutation, human), and HT29 (KRAS wild type, human) cells were treated with simvastatin (10 µM) and FPP (5 µM) or GGPP (5 µM) for 24 hours, stained with Annexin-V-647, and analyzed using flow cytometry (n=4–12). (E) CCK8 assay of KRASmut and KRASwt CRC cell lines (n=3). (F) Levels of p-ERK1/2 and t-ERK1/2 on CT26 cells were assessed using flow cytometry (n=2–6). (G) Genetic information on PDCs. (H) PDCs were treated with simvastatin at the indicated conditions, and cell viability (%) was assessed using the Water Soluble Tetrazolium Salts cell proliferation assay (n=15–36). The data are shown as mean±SEM. Student’s t-test (D, H) or one-way ANOVA with Tukey’s post-hoc test (C–F) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; CRC, colorectal cancer; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; PDCs, patient-derived cancer cells.CC BY-NC · PubMed Central
Figure 2 Statin induces immunogenic cell death of cancer cells. (A–C) CT26 cells were treated with simvastatin (10 µM) and FPP (5 µM) or GGPP (5 µM) for 4 hours. (A) Representative western blot image showing the levels of ER-stress response markers (elf2α, p-elf2α, ATF4, and CHOP) and a loading control (Glyceraldehyde 3-phosphate dehydrogenase). (B) Quantification of p-elF2α evaluated by western blotting. (C) Expression of CRT (n=5–11) and ERP57 (n=4–5) was assessed using flow cytometry. (D) Representative confocal image of expression of CRT (green) and wheat germ agglutinin (red). (E) CT26 cells were treated with simvastatin (10 µM) for 24 hours. Representative western blot image of the levels of HMGB1 and HSP70 in cell lysates. (F–H) CT26 tumor-bearing syngeneic mice were injected with simvastatin (20 mg/kg) for seven times daily. After 24 hours, the tumors were extracted. (F) The levels of ERK1/2, p-ERK1/2, and (G, H) CRT in the CT26 tumors as assessed using flow cytometry (ERK1/2: n=8; p-ERK1/2: n=8; CRT: n=8). (I) CT26 cells were treated with con-siRNA (100 nM), KRAS-siRNA (100 nM), and simvastatin (10 µM) for 24 hours. Expression of CRT (n=4) or ERP57 (n=4) was assessed using flow cytometry. (J–L) Calu-1 and H23 cancer cells were treated with AMG-510 (10 µM) and simvastatin (10 µM) for 24 hours or 48 hours. (J) Annexin-V assay results indicated the conditions of CT26 cancer cells (n=3–5). CRT and ERP57 expression on (K) Calu-1 and (L) H23 tumor cells after 24 hours was assessed using flow cytometry (n=3–5). The data are shown as mean±SEM. Student’s t-test (B, F, G) or one-way ANOVA with Tukey’s post-hoc test (C and I–L) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; CRT, calreticulin; ER, endoplasmic reticulum; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; HMGB1, high-mobility group box 1; HSP70, heat-shock protein 70.
Figure 2 Statin induces immunogenic cell death of cancer cells. (A–C) CT26 cells were treated with simvastatin (10 µM) and FPP (5 µM) or GGPP (5 µM) for 4 hours. (A) Representative western blot image showing the levels of ER-stress response markers (elf2α, p-elf2α, ATF4, and CHOP) and a loading control (Glyceraldehyde 3-phosphate dehydrogenase). (B) Quantification of p-elF2α evaluated by western blotting. (C) Expression of CRT (n=5–11) and ERP57 (n=4–5) was assessed using flow cytometry. (D) Representative confocal image of expression of CRT (green) and wheat germ agglutinin (red). (E) CT26 cells were treated with simvastatin (10 µM) for 24 hours. Representative western blot image of the levels of HMGB1 and HSP70 in cell lysates. (F–H) CT26 tumor-bearing syngeneic mice were injected with simvastatin (20 mg/kg) for seven times daily. After 24 hours, the tumors were extracted. (F) The levels of ERK1/2, p-ERK1/2, and (G, H) CRT in the CT26 tumors as assessed using flow cytometry (ERK1/2: n=8; p-ERK1/2: n=8; CRT: n=8). (I) CT26 cells were treated with con-siRNA (100 nM), KRAS-siRNA (100 nM), and simvastatin (10 µM) for 24 hours. Expression of CRT (n=4) or ERP57 (n=4) was assessed using flow cytometry. (J–L) Calu-1 and H23 cancer cells were treated with AMG-510 (10 µM) and simvastatin (10 µM) for 24 hours or 48 hours. (J) Annexin-V assay results indicated the conditions of CT26 cancer cells (n=3–5). CRT and ERP57 expression on (K) Calu-1 and (L) H23 tumor cells after 24 hours was assessed using flow cytometry (n=3–5). The data are shown as mean±SEM. Student’s t-test (B, F, G) or one-way ANOVA with Tukey’s post-hoc test (C and I–L) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; CRT, calreticulin; ER, endoplasmic reticulum; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; HMGB1, high-mobility group box 1; HSP70, heat-shock protein 70.CC BY-NC · PubMed Central
Figure 3 Statin enhances the functions of DCs against cancer. (A, B) CMFDA-stained BMDMs or BMDCs were coincubated with CT26 cells treated with the indicated drugs. Representative immunofluorescence images of pHrodo-SE-labeled CT26 cells (red) against green CMFDA-labeled BMDMs or BMDCs (left). Scale bar: 50 µm. Phagocytosis (%) was calculated based on the total number of BMDMs (A; n=7–14) or BMDCs (B; n=12–23) containing CT26 cells (right). (C, D) CT26 and MC38 tumor-bearing syngeneic mice were injected with simvastatin (20 mg/kg) for seven times daily. After 24 hours, DCs (CD11c+ cells) were sorted from extracted tumor tissues. (C) Gene expression in DCs (CD11c+ cells) sorted from CT26 or MC38 tumors using the NanoString nCounter System (CT26: n=3; MC38: n=3). (D) Cross-presentation-related mRNA expression in DCs (CD11c+ cells) sorted from CT26 or MC38 tumors determined by NanoString nCounter System (CT26: n=3; MC38: n=3). (E) Prophylactic vaccine effect of BMDCs coincubated with CT26 cells that were treated with simvastatin (10 µM) or frozen and thawed vs challenged CT26 cells (n=7). These data are shown as mean±SEM. One-way ANOVA with Tukey’s post-hoc test (A, B), Student’s t-test (D), or Kaplan–Meier analysis followed by long-rank test (E) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; BMDCs, bone marrow-derived dendritic cells; BMDMs, bone marrow-derived macrophages; DCs, dendritic cells.
Figure 3 Statin enhances the functions of DCs against cancer. (A, B) CMFDA-stained BMDMs or BMDCs were coincubated with CT26 cells treated with the indicated drugs. Representative immunofluorescence images of pHrodo-SE-labeled CT26 cells (red) against green CMFDA-labeled BMDMs or BMDCs (left). Scale bar: 50 µm. Phagocytosis (%) was calculated based on the total number of BMDMs (A; n=7–14) or BMDCs (B; n=12–23) containing CT26 cells (right). (C, D) CT26 and MC38 tumor-bearing syngeneic mice were injected with simvastatin (20 mg/kg) for seven times daily. After 24 hours, DCs (CD11c+ cells) were sorted from extracted tumor tissues. (C) Gene expression in DCs (CD11c+ cells) sorted from CT26 or MC38 tumors using the NanoString nCounter System (CT26: n=3; MC38: n=3). (D) Cross-presentation-related mRNA expression in DCs (CD11c+ cells) sorted from CT26 or MC38 tumors determined by NanoString nCounter System (CT26: n=3; MC38: n=3). (E) Prophylactic vaccine effect of BMDCs coincubated with CT26 cells that were treated with simvastatin (10 µM) or frozen and thawed vs challenged CT26 cells (n=7). These data are shown as mean±SEM. One-way ANOVA with Tukey’s post-hoc test (A, B), Student’s t-test (D), or Kaplan–Meier analysis followed by long-rank test (E) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; BMDCs, bone marrow-derived dendritic cells; BMDMs, bone marrow-derived macrophages; DCs, dendritic cells.CC BY-NC · PubMed Central
Figure 4 Statin triggers CD8+ T-cell-mediated eradication of KRAS mutant tumors. (A–I) CT26 and MC38 tumor-bearing syngeneic mice were injected with simvastatin (20 mg/kg) for seven times daily. TDLNs and tumor tissues were extracted 1 day after the end of treatment and analyzed using flow cytometry. (A) Expression of H2Kd in DCs (CD11c+ cells) of CT26 tumors (n=4). (B) Expression of CD40, CD80, or CD86 in DCs (CD11c+ cells) of TDLN (CT26: n=5–6; MC38, n=4). (C) DCs (CD11c+ cells) of TDLN were coincubated with CD8+ T cells from CT26 or MC38 tumor models for 72 hours. The cross-prime ability of DCs from TDLN was determined based on the released IFN-γ analyzed using IFN-γ ELISA kit (CT26: n=5; MC38: n=5). (D) Percentage of CD8+ T cells in the TDLNs of CT26 and MC38 tumor models (CT26: n=6; MC38: n=4). (E) Expression of CD44 on CD8+ T cells (CD45.2+CD3+CD8+) in TDLN (left) (CT26: n=4; MC38: n=4). Representative histograms of CD44 expression on CD8+ T cells isolated from CT26 and MC38 TDLN. (Right) (F) Proportion of CD8+ T cells (CD45.2+CD3+CD8+) in tumors (left) (CT26: n=4; MC38: n=5). Representative plots of CD8+ T cells. (Right) (G) The expression of CD69 on CD8+ T cells in CT26 tumors (CT26: n=4). (H) The expression of CD107α on CD8+ T cells in CT26 and MC38 tumors (CT26: n=4; MC38: n=4). (I, J) CT26 tumor models were injected with simvastatin (20 mg/kg), neutralizing CD4 (10 mg/kg), neutralizing CD8 (10 mg/kg), or control IgG. (I) Tumor weight (g) was measured at the end of the experiment (CT26: n=10; MC38: n=8). (J) Tumor volume (mm3) was measured in indicated periods (n=7). These data are shown as mean±SEM. Student’s t-test (A–H) or one-way ANOVA with Tukey’s post-hoc test (J) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; DCs, dendritic cells; IFN-γ, interferon-γ; TDLN, tumor-draining lymph nodes.
Figure 4 Statin triggers CD8+ T-cell-mediated eradication of KRAS mutant tumors. (A–I) CT26 and MC38 tumor-bearing syngeneic mice were injected with simvastatin (20 mg/kg) for seven times daily. TDLNs and tumor tissues were extracted 1 day after the end of treatment and analyzed using flow cytometry. (A) Expression of H2Kd in DCs (CD11c+ cells) of CT26 tumors (n=4). (B) Expression of CD40, CD80, or CD86 in DCs (CD11c+ cells) of TDLN (CT26: n=5–6; MC38, n=4). (C) DCs (CD11c+ cells) of TDLN were coincubated with CD8+ T cells from CT26 or MC38 tumor models for 72 hours. The cross-prime ability of DCs from TDLN was determined based on the released IFN-γ analyzed using IFN-γ ELISA kit (CT26: n=5; MC38: n=5). (D) Percentage of CD8+ T cells in the TDLNs of CT26 and MC38 tumor models (CT26: n=6; MC38: n=4). (E) Expression of CD44 on CD8+ T cells (CD45.2+CD3+CD8+) in TDLN (left) (CT26: n=4; MC38: n=4). Representative histograms of CD44 expression on CD8+ T cells isolated from CT26 and MC38 TDLN. (Right) (F) Proportion of CD8+ T cells (CD45.2+CD3+CD8+) in tumors (left) (CT26: n=4; MC38: n=5). Representative plots of CD8+ T cells. (Right) (G) The expression of CD69 on CD8+ T cells in CT26 tumors (CT26: n=4). (H) The expression of CD107α on CD8+ T cells in CT26 and MC38 tumors (CT26: n=4; MC38: n=4). (I, J) CT26 tumor models were injected with simvastatin (20 mg/kg), neutralizing CD4 (10 mg/kg), neutralizing CD8 (10 mg/kg), or control IgG. (I) Tumor weight (g) was measured at the end of the experiment (CT26: n=10; MC38: n=8). (J) Tumor volume (mm3) was measured in indicated periods (n=7). These data are shown as mean±SEM. Student’s t-test (A–H) or one-way ANOVA with Tukey’s post-hoc test (J) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; DCs, dendritic cells; IFN-γ, interferon-γ; TDLN, tumor-draining lymph nodes.CC BY-NC · PubMed Central
Figure 5 Combination therapy of statin and oxaliplatin effectively induces antitumor immune responses. (A) Expression of CRT was assessed using flow cytometry (n=4). (B) CMFDA-stained BMDCs were coincubated with CT26 cells treated with the indicated drugs. Phagocytosis (%) was calculated based on the total number of BMDCs (green) containing CT25 cells (red) (n=7–12). Scale bar: 50 µm. (C–H) CT26 tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg). (C) Tumor volume (mm3) was measured in the indicated periods (n=19). (D) Tumor weight (g) was measured at the end of the experiment (n=19). (E, F) Cross-prime ability of DCs from TDLN was determined based on the released IFN-γ (E, n=5) and on CD107α expression on CD8+ T cells analyzed (F, n=4). (G) Proportion of CD8+ T cells (CD45.2+CD3+CD8+ cells) in tumors (left) (n=10) and representative quadrant plots of CD8+ T cells in CT26 tumors (right). (H) Proportion of IFN-γ+ cells in CD8+ T cells (CD45.2+CD3+CD8+ cells) in tumors (n=3). (I–L) B6.129-Krastm3Bbd/J lung and KIC pancreatic tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg). (I) The number of tumor nodules measured at the end of the experiment (left) (n=6–7) and representative image of KRASmut lung cancer at the end of the experiment (right). (J) Tumor fraction (%) measured at the end of the experiment (left) (n=6–10) and representative H&E staining of KRASmut lung cancer (right). (K) Survival rate in the KIC models following combination treatment (n=10). (L) Representative microscopic image of CD8+ T-cell infiltration; scale bar: 50 µm. The data are shown as mean±SEM. One-way ANOVA with Tukey’s post-hoc test (A–J) or Kaplan–Meier analysis using long-rank test (K) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; BMDCs, bone marrow-derived dendritic cells; CRT, calreticulin; DCs, dendritic cells; TDLN, tumor-draining lymph nodes.
Figure 5 Combination therapy of statin and oxaliplatin effectively induces antitumor immune responses. (A) Expression of CRT was assessed using flow cytometry (n=4). (B) CMFDA-stained BMDCs were coincubated with CT26 cells treated with the indicated drugs. Phagocytosis (%) was calculated based on the total number of BMDCs (green) containing CT25 cells (red) (n=7–12). Scale bar: 50 µm. (C–H) CT26 tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg). (C) Tumor volume (mm3) was measured in the indicated periods (n=19). (D) Tumor weight (g) was measured at the end of the experiment (n=19). (E, F) Cross-prime ability of DCs from TDLN was determined based on the released IFN-γ (E, n=5) and on CD107α expression on CD8+ T cells analyzed (F, n=4). (G) Proportion of CD8+ T cells (CD45.2+CD3+CD8+ cells) in tumors (left) (n=10) and representative quadrant plots of CD8+ T cells in CT26 tumors (right). (H) Proportion of IFN-γ+ cells in CD8+ T cells (CD45.2+CD3+CD8+ cells) in tumors (n=3). (I–L) B6.129-Krastm3Bbd/J lung and KIC pancreatic tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg). (I) The number of tumor nodules measured at the end of the experiment (left) (n=6–7) and representative image of KRASmut lung cancer at the end of the experiment (right). (J) Tumor fraction (%) measured at the end of the experiment (left) (n=6–10) and representative H&E staining of KRASmut lung cancer (right). (K) Survival rate in the KIC models following combination treatment (n=10). (L) Representative microscopic image of CD8+ T-cell infiltration; scale bar: 50 µm. The data are shown as mean±SEM. One-way ANOVA with Tukey’s post-hoc test (A–J) or Kaplan–Meier analysis using long-rank test (K) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; BMDCs, bone marrow-derived dendritic cells; CRT, calreticulin; DCs, dendritic cells; TDLN, tumor-draining lymph nodes.CC BY-NC · PubMed Central
Figure 6 Combination therapy sensitizes tumors to PD-1 blockade. (A–D) CT26 tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg). (A) Representative multiplex IHC image of CD8 (green), PD-L1 (red), and DAPI (blue); scale bar: 2 mm (left), 200 µm (middle), and 50 µm (right). (B) Representative histogram of PD-L1 expression. (C) PD-L1 expression on CD45− cells or CD45+ cells in CT26 tumors was assessed using flow cytometry (n=5). (D) Representative multiplex IHC image of CD8 (green), PD-L1 (red), and DAPI (blue) about combined therapy; scale bar: 300 µm. (E–G) CT26 tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg) with and without anti-PD-1 antibodies (10 mg/kg). (E) Illustration of the dosing schedule. (F) Tumor volume (mm3) was measured in the indicated period (n=15). (G) Survival rate in the CT26 syngeneic tumor model following the ternary combination treatment (n=10). The data are shown as mean±SEM. One-way ANOVA with Tukey’s post-hoc test (C, F) or Kaplan-Meier analysis using long-rank test (G) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; IHC, immunohistochemistry.
Figure 6 Combination therapy sensitizes tumors to PD-1 blockade. (A–D) CT26 tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg). (A) Representative multiplex IHC image of CD8 (green), PD-L1 (red), and DAPI (blue); scale bar: 2 mm (left), 200 µm (middle), and 50 µm (right). (B) Representative histogram of PD-L1 expression. (C) PD-L1 expression on CD45− cells or CD45+ cells in CT26 tumors was assessed using flow cytometry (n=5). (D) Representative multiplex IHC image of CD8 (green), PD-L1 (red), and DAPI (blue) about combined therapy; scale bar: 300 µm. (E–G) CT26 tumor models were injected with simvastatin (20 mg/kg) and oxaliplatin (5 mg/kg) with and without anti-PD-1 antibodies (10 mg/kg). (E) Illustration of the dosing schedule. (F) Tumor volume (mm3) was measured in the indicated period (n=15). (G) Survival rate in the CT26 syngeneic tumor model following the ternary combination treatment (n=10). The data are shown as mean±SEM. One-way ANOVA with Tukey’s post-hoc test (C, F) or Kaplan-Meier analysis using long-rank test (G) determined statistical significance. The experiment was conducted at least three times with similar results. ANOVA, analysis of variance; IHC, immunohistochemistry.CC BY-NC · PubMed Central
Figure 7 Graphical abstract of the anticancer immunotherapeutic strategy using by statins.
Figure 7 Graphical abstract of the anticancer immunotherapeutic strategy using by statins.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 90

Metadata

Authors
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., Han, J., Woo, J., Cho, Y., Jeong, C., Park, S.-Y., Roberts, T. M., Cho, Y. B., & Kim, I.-S.
Affiliations
  • Harvard University (US)
  • Korea University Anam Hospital (KR)
  • Samsung Medical Center (KR)
  • Korea University (KR)
  • Korea Institute of Science and Technology (KR)
  • Kyung Hee University (KR)
  • Dongguk University (KR)
Corresponding author
  • Kim, Seohyun
  • Cho, Yong Beom
  • Kim, In-San
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-07
Volume
9
Issue
7
Pages
e002474
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3183405237
Cited by
82
References
49
Citations by year
2026: 12 · 2025: 19 · 2024: 12 · 2023: 19 · 2022: 15 · 2021: 5
FWCI
5.07
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • KU-KIST Graduate School of Conversing Science and Technology Program
  • the KIST Institutional Program
  • Ministry of Science and ICT (2020R1C1C1003539, 2017R1A3B1023418)
  • Korea Health Industry Development Institute (HI19C0753)
  • SMC-KIST Collaborative Research Program
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
statins, KRAS mutation, Ras prenylation, endoplasmic reticulum stress, immunogenic cell death, cancer immunotherapy, CD8+ T cell immunity, anti-PD-1 resistance, tumor immune microenvironment, colorectal cancer, lung cancer, pancreatic cancer, farnesyl pyrophosphate, geranylgeranyl pyrophosphate
MeSH terms
Animals, Humans, Male, Mutation, Transfection, Proto-Oncogene Proteins p21(ras), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mice, Endoplasmic Reticulum Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. https://app.cochat.ai/papers/10.1136/jitc-2021-002474
The paper
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., Han, J., Woo, J., Cho, Y., Jeong, C., Park, S.-Y., Roberts, T. M., Cho, Y. B., & Kim, I.-S. (2021). Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.